GHODRAT SHOLEVAR: Open Payments
NPI 1649324955 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,242 in 50 payments from 9 companies in 2025. Trend: 2023 $534 · 2024 $671 · 2025 $1,242
Food & beverage: $1,242
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $370 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $224 |
| ABBVIE INC. | 10 | $218 |
| Lundbeck LLC | 6 | $151 |
| Janssen Pharmaceuticals, Inc | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Almatica Pharma LLC | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 2 | $50 |
| Alkermes, Inc. | 1 | $19 |
Products named: INGREZZA, CAPLYTA, REXULTI, VRAYLAR, INVEGA SUSTENNA, LOREEV XR, COBENFY, ARISTADA.
Industry payments across PA — which companies pay providers there.
